The US Food and Drug Administration (FDA) has approved Pfizer’s Xejanz XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX).

Xejanz and Xejanz XR (tofacitinib citrate) is a prescription medicine called a Janus kinase (JAK) inhibitor. Xejanz is approved in more than 45 countries around the world for the treatment of moderate to severe RA as a second-line therapy after failure of one or more disease-modifying antirheumatic drugs.

Source: Pfizer